Regulatory sequence analysis of semaphorin 4D 5' non-coding region.

The role of Semaphorin 4D (Sema4D) in hypoxia-related processes is well established, particularly in angiogenesis. It is known that Sema4D is regulated by hypoxia-inducible factor 1 (HIF-1), similar to vascular endothelial growth factor (VEGF). However, the precise regulatory sequences in the 5' non-coding region of Sema4D remain unclear. Prior research has identified Sema4D as a hypoxia effector, but the mechanisms governing its expression under low oxygen conditions are not fully understood. This gap motivated further investigation into the sequence characteristics of the 5' non-coding region. No prior work had resolved the functional significance of specific hypoxia response elements (HREs) in this region. Understanding these regulatory elements is essential for deciphering how Sema4D contributes to tumor angiogenesis. Researchers have not yet determined whether nucleotide variations in this region affect gene expression. This uncertainty drove the need for a detailed sequence and functional analysis. The study aimed to fill this knowledge gap by examining the 5' non-coding region of Sema4D in both cancer and normal cells.

This study aimed to identify and characterize the regulatory sequences in the 5' non-coding region of Sema4D. Researchers focused on the region before the ATG start codon, where hypoxia response elements (HREs) are likely to reside. The goal was to determine which HREs are functional and how they influence Sema4D expression. The study also sought to compare the sequence characteristics between cancer and normal cell lines. By performing sequencing and alignment, the team aimed to detect nucleotide variations that might affect gene regulation. Functional analysis was conducted using point mutagenesis and luciferase assays. The purpose was to assess the impact of these variations on gene expression efficiency. This approach allowed the researchers to link specific sequence changes to altered regulatory activity. The study's findings could contribute to the development of anti-angiogenesis strategies for cancer treatment.

The researchers first screened the 5' non-coding region of Sema4D for potential HREs. They analyzed a 1275 base pair (bp) segment before the ATG start codon. Sequencing and alignment were performed across 11 cancer and 4 normal cell lines. This step identified nucleotide variations specific to cancer cells. Next, the team cloned the identified HREs and introduced point mutations. Luciferase assays were used to measure the functional impact of these mutations. Secondary structure prediction was also conducted to assess how mutations might alter gene structure. The study compared the expression levels in human umbilical vein endothelial cells (HUVEC) and Caco-2 cells. This method allowed the researchers to evaluate the role of each HRE in different cell types. The combination of mutagenesis and functional assays provided a comprehensive view of the regulatory mechanisms. The approach enabled the team to distinguish between functional and non-functional HREs.

The analysis identified four potential HREs (HRE1-4) within the 1275 bp region. Functional assays revealed that HRE2 and HRE4 were binding sites for HIF-1α. These two HREs showed distinct regulatory effects in HUVEC and Caco-2 cells. Three nucleotide variants were frequently observed in cancer cell lines: T471C, A600G, and C862T. The site variation rates were 72.7%, 18.2%, and 72.7% for these variants, respectively. Luciferase assays showed that T471C and C862T significantly increased gene expression efficiency. Secondary structure predictions indicated that these mutations altered the gene's RNA structure. The results highlight the importance of these variants in Sema4D regulation. The study provides evidence that sequence variations in the 5' non-coding region influence gene expression. These findings suggest that specific mutations enhance the regulatory activity of Sema4D. The data support the hypothesis that HRE2 and HRE4 play key roles in hypoxia-induced expression.

The study demonstrates that the 5' non-coding region of Sema4D contains functional HREs that regulate gene expression. HRE2 and HRE4 are identified as HIF-1α binding sites with distinct regulatory roles. The presence of T471C and C862T mutations increases expression efficiency in cancer cells. These mutations also alter the RNA secondary structure of the gene. The findings enhance understanding of how Sema4D is regulated under hypoxic conditions. The study supports the idea that sequence variations in this region affect gene function. The results may inform the development of anti-angiogenesis therapies for malignancies. The authors suggest that targeting these regulatory elements could offer new treatment strategies. The study does not propose new drug targets but highlights the importance of sequence analysis. The conclusions are based on the observed functional differences between HREs and mutations.